Clinical Trial Forges New Standard of Care for Advanced Hodgkin Lymphoma
Adding the immunotherapy drug nivolumab to a mix of chemotherapy drugs outperformed the current standard therapy for advanced Hodgkin lymphoma in a large clinical trial. The new study is rapidly changing how patients are being treated internationally and at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, said Craig Moskowitz, M.D., Sylvester’s physician-in-chief.



